Hub : Traits :

Cholesterol lowering medication

165 significantly associated models · 68 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	15752716	17413769	3	1	3.6e-08	1.1e-07	4.6e-01	98	C1orf89
2	1	26327671	27882335	3	1	1.8e-08	3.3e-06	5.3e-01	98	PIGV
3	1	62207254	63844736	3	1	8.2e-11	2.4e-10	3.8e-01	98	DOCK7
4	1	108854166	110733794	6	1	4.4e-32	9.3e-32	1.0e+00	100	PSRC1
5	2	20529948	21958745	1	1	2.1e-25	9.5e-26	1.0e+00	100	APOB
6	2	26883355	28414302	4	1	3.7e-14	7.1e-14	1.0e+00	100	FNDC4
7	2	43791363	44307450	1	1	5.4e-08	1.9e-17	1.8e-12	31	ABCG5
8	5	73969058	75594743	4	1	1.6e-14	1.5e-14	5.8e-02	94	HMGCR
9	6	160071844	161571560	2	2	3.2e-12	5.0e-15	1.5e-04	76	SLC22A3
10	8	18003897	18505600	1	1	1.3e-07	1.6e-10	2.4e-04	67	NAT2
11	8	19547307	20071503	1	1	3.2e-08	5.2e-09	2.4e-03	73	LPL
12	9	106846396	108380721	1	1	2.8e-07	3.1e-07	6.4e-02	87	ABCA1
13	9	135883620	136399075	1	1	1.1e-09	1.3e-09	5.7e-03	79	ABO
14	11	63044593	64701030	2	2	1.6e-08	1.8e-07	1.0e+00	100	COX8A VEGFB
15	11	115953897	117800682	5	2	4.1e-25	2.2e-29	3.2e-01	99	PAFAH1B2 ZNF259
16	13	46645740	48066565	1	1	1.9e-07	5.5e-08	1.0e+00	100	ESD
17	13	114052470	115106996	1	1	6.2e-08	2.7e-05	1.3e-01	87	RASA3
18	16	71374298	72800567	3	1	7.9e-08	2.0e-07	1.0e+00	100	TXNL4B
19	17	27207120	28933576	5	1	1.8e-08	3.7e-08	2.6e-01	96	GIT1
20	19	9982334	12196190	10	9	1.6e-15	1.4e-42	5.0e-07	86	C19orf80 CDKN2D KANK2 RGL3 SMARCA4 SPC24
21	19	44649590	46098885	3	3	2.3e-13	2.1e-86	6.7e-65	25	APOC2 PVRL2 TOMM40
22	19	48918157	49424381	1	1	1.5e-09	9.2e-07	2.9e-01	95	NTN5
23	20	39567774	40229720	2	1	4.0e-08	1.9e-07	6.1e-02	87	LPIN3
24	20	62008975	62912463	3	1	8.1e-09	1.8e-08	4.0e-01	98	OPRL1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	61.15	24	18	40.0	0.92	4.7e-12	ABCA1 ABCG5 ABO APOB APOC2 C19orf80 CDKN2D DOCK7 FNDC4 HMGCR KANK2 LPIN3 NTN5 PAFAH1B2 PIGV PSRC1 PVRL2 RGL3 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B ZNF259
High cholesterol (Self-reported)	45.81	30	27	60.0	0.98	5.4e-25	ABCA1 ABCG5 ABO APOB APOC2 C19orf80 CDKN2D COX8A DOCK7 FNDC4 HMGCR KANK2 LPIN3 LPL NAT2 NTN5 OPRL1 PAFAH1B2 PIGV PSRC1 PVRL2 RASA3 RGL3 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B VEGFB ZNF259
Triglycerides	40.01	11	7	15.6	0.76	6.2e-03	APOB APOC2 DOCK7 FNDC4 LPL NAT2 PAFAH1B2 PVRL2 SLC22A3 TXNL4B ZNF259
Medication: Cholesterol lowering	24.71	25	18	40.0	0.98	1.8e-20	ABCG5 ABO APOB APOC2 C19orf80 DOCK7 FNDC4 HMGCR KANK2 LPL NAT2 NTN5 OPRL1 PAFAH1B2 PIGV PSRC1 PVRL2 RGL3 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B VEGFB ZNF259
Medication: Simvastatin	22.74	26	20	44.4	0.99	2.7e-24	ABCG5 ABO APOB APOC2 C19orf80 COX8A DOCK7 FNDC4 HMGCR LPIN3 LPL NAT2 NTN5 OPRL1 PAFAH1B2 PIGV PSRC1 PVRL2 RGL3 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B VEGFB ZNF259
Medication: Atorvastatin	19.77	21	11	24.4	0.99	3.2e-19	ABCA1 ABO APOB C19orf80 CDKN2D DOCK7 FNDC4 HMGCR KANK2 LPL NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B ZNF259
HDL Cholesterol	13.78	9	4	8.9	-0.50	1.7e-01	ABCA1 APOB APOC2 LPL PIGV PSRC1 PVRL2 TOMM40 ZNF259
Alzheimer’s Disease (including proxy)	10.15	3	3	6.7	0.00	1.0e+00	APOC2 PVRL2 TOMM40
Cardiovascular Disease	9.43	23	18	40.0	0.98	7.9e-18	ABCG5 APOB C1orf89 DOCK7 FNDC4 GIT1 HMGCR LPL NAT2 NTN5 OPRL1 PAFAH1B2 PIGV PSRC1 PVRL2 RGL3 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B VEGFB ZNF259
Medication for cholesterol, blood pressure or diabetes	9.27	17	5	11.1	-0.99	1.9e-14	APOB C19orf80 FNDC4 GIT1 HMGCR LPL NAT2 NTN5 OPRL1 PAFAH1B2 PIGV PSRC1 SMARCA4 SPC24 TOMM40 TXNL4B ZNF259
Blood clot in the leg (DVT)	8.00	1	1	2.2	0.00	1.0e+00	ABO
Deep venous thrombosis (DVT) (self-reported)	7.75	1	1	2.2	0.00	1.0e+00	ABO
Medication for cholesterol	7.44	13	2	4.4	-0.97	1.0e-08	DOCK7 FNDC4 HMGCR NTN5 PAFAH1B2 PIGV PSRC1 PVRL2 RGL3 SLC22A3 SPC24 TXNL4B VEGFB
Coronary Artery Disease (CAD)	7.25	6	3	6.7	0.97	4.3e-04	ABO LPL PSRC1 SLC22A3 SMARCA4 ZNF259
Angina (self-reported)	6.73	7	2	4.4	0.99	4.5e-06	ABCG5 C19orf80 LPL OPRL1 PSRC1 SLC22A3 SPC24
Angina	6.61	9	1	2.2	0.99	3.1e-08	ABCG5 APOC2 C19orf80 GIT1 LPL OPRL1 PSRC1 SLC22A3 SPC24
Medication: Aspirin	6.40	8	1	2.2	0.98	1.6e-05	C19orf80 GIT1 LPL OPRL1 PSRC1 SLC22A3 SPC24 VEGFB
Medication: Aspirin	6.32	8	1	2.2	0.98	1.5e-05	C19orf80 GIT1 LPL OPRL1 PSRC1 SLC22A3 SPC24 VEGFB
Illnesses of father: Heart disease	6.31	7	2	4.4	0.98	2.1e-05	ABO LPL OPRL1 PSRC1 SLC22A3 SMARCA4 SPC24
Alzheimer’s Disease (in mother)	6.30	3	3	6.7	0.00	1.0e+00	APOC2 PVRL2 TOMM40
Heart attack/myocardial infarction (self-reported)	5.49	5	1	2.2	0.98	3.1e-03	C19orf80 LPL PSRC1 SLC22A3 SPC24
Heart attack	5.48	6	1	2.2	0.98	3.8e-04	C19orf80 GIT1 LPL PSRC1 SLC22A3 SPC24
Heart disease (siblings)	4.19	3	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3 ZNF259
Gout (self-reported)	4.05	1	1	2.2	0.00	1.0e+00	FNDC4
Number of self-reported non-cancer illnesses	3.99	5	1	2.2	1.00	2.0e-07	FNDC4 GIT1 NTN5 OPRL1 VEGFB
Heart disease (mother)	3.92	2	0	0.0	0.00	1.0e+00	ABO SLC22A3
Number of treatments/medications taken	3.77	3	0	0.0	0.00	1.0e+00	FNDC4 NTN5 PSRC1
Fasting Glucose	3.61	1	1	2.2	0.00	1.0e+00	FNDC4
Waist Hip Ratio (WHR)	3.48	9	5	11.1	0.86	1.6e-03	ABCA1 KANK2 LPIN3 LPL NTN5 OPRL1 SLC22A3 SMARCA4 VEGFB
Alcohol intake frequency.	3.46	3	2	4.4	0.00	1.0e+00	FNDC4 LPIN3 NTN5
Medication: Allopurinol	3.45	2	1	2.2	0.00	1.0e+00	FNDC4 PIGV
Blood Platelet Count	3.23	15	10	22.2	0.07	8.0e-01	APOC2 COX8A DOCK7 FNDC4 GIT1 HMGCR LPIN3 LPL NTN5 PAFAH1B2 PIGV PVRL2 TOMM40 TXNL4B ZNF259
Vascular/heart problems diagnosed by doctor	3.01	6	3	6.7	-0.70	1.2e-01	ABO GIT1 NTN5 OPRL1 PIGV VEGFB
Type 2 Diabetes (T2D) (2018)	2.84	3	1	2.2	0.00	1.0e+00	FNDC4 LPL VEGFB
Alzheimer’s Disease (in father)	2.81	3	1	2.2	0.00	1.0e+00	APOC2 PVRL2 TOMM40
Diabetes diagnosed by doctor	2.80	2	1	2.2	0.00	1.0e+00	FNDC4 VEGFB
Blood White Count	2.77	11	4	8.9	-0.11	7.4e-01	ABO DOCK7 FNDC4 GIT1 KANK2 LPIN3 PAFAH1B2 PVRL2 RASA3 SMARCA4 VEGFB
Trunk fat-free mass	2.73	8	6	13.3	-0.87	1.1e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4 SPC24
Trunk predicted mass	2.73	8	6	13.3	-0.87	1.1e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4 SPC24
Pulse rate, automated reading	2.72	5	1	2.2	0.08	8.9e-01	ABO APOB DOCK7 FNDC4 KANK2
Medication: Metformin	2.65	3	1	2.2	0.00	1.0e+00	ABO FNDC4 LPL
Illnesses of siblings	2.65	1	0	0.0	0.00	1.0e+00	GIT1
Father's age at death	2.62	3	0	0.0	0.00	1.0e+00	ABO LPL PSRC1
Medication: Blood pressure	2.60	3	1	2.2	0.00	1.0e+00	NTN5 PIGV VEGFB
Arm fat-free mass (right)	2.58	7	5	11.1	-0.88	1.9e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4
Arm predicted mass (left)	2.58	7	5	11.1	-0.88	1.8e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4
Diabetes (mother)	2.57	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Arm predicted mass (right)	2.57	7	4	8.9	-0.87	2.1e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4
Hypertension (Self-reported)	2.54	6	5	11.1	0.67	1.5e-01	ABO GIT1 NTN5 OPRL1 PIGV VEGFB
Whole body fat-free mass	2.54	6	4	8.9	-0.86	6.0e-03	FNDC4 HMGCR PSRC1 SLC22A3 SMARCA4 SPC24
Whole body water mass	2.54	6	4	8.9	-0.86	6.7e-03	FNDC4 HMGCR PSRC1 SLC22A3 SMARCA4 SPC24
Arm fat-free mass (left)	2.50	7	4	8.9	-0.87	2.5e-03	ABO FNDC4 HMGCR NTN5 PSRC1 SLC22A3 SMARCA4
High blood pressure	2.44	6	3	6.7	0.62	1.9e-01	ABO GIT1 NTN5 OPRL1 PIGV VEGFB
Diabetes (self-reported)	2.44	1	1	2.2	0.00	1.0e+00	FNDC4
Basal metabolic rate	2.37	5	4	8.9	-0.87	1.2e-02	FNDC4 HMGCR PSRC1 SLC22A3 SMARCA4
Lung FEV1/FVC ratio	2.34	6	4	8.9	-0.04	9.3e-01	ABO C1orf89 COX8A GIT1 NTN5 PSRC1
Leg fat-free mass (right)	2.26	6	3	6.7	-0.86	1.3e-02	FNDC4 HMGCR PSRC1 SLC22A3 SMARCA4 SPC24
Leg predicted mass (right)	2.26	6	3	6.7	-0.86	1.3e-02	FNDC4 HMGCR PSRC1 SLC22A3 SMARCA4 SPC24
Alcohol intake versus 10 years previously	2.25	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Leg predicted mass (left)	2.24	4	3	6.7	-0.99	1.9e-03	FNDC4 HMGCR SLC22A3 SMARCA4
Leg fat-free mass (left)	2.23	4	3	6.7	-0.99	2.0e-03	FNDC4 HMGCR SLC22A3 SMARCA4
Impedance of arm (left)	2.16	5	3	6.7	0.83	7.9e-02	ABO FNDC4 HMGCR KANK2 OPRL1
Primary Biliary Cirrhosis	2.13	2	0	0.0	0.00	1.0e+00	CDKN2D SMARCA4
Systolic Blood Pressure	2.09	10	3	6.7	0.95	3.3e-05	FNDC4 NTN5 OPRL1 PAFAH1B2 PIGV RGL3 SLC22A3 SMARCA4 TOMM40 VEGFB
Impedance of arm (right)	2.09	5	3	6.7	0.82	9.0e-02	ABO FNDC4 HMGCR KANK2 OPRL1
Comparative height size at age 10	2.00	8	4	8.9	-0.82	4.0e-03	FNDC4 GIT1 KANK2 NTN5 PIGV PSRC1 SLC22A3 SPC24
Medication: Ramipril	1.99	1	0	0.0	0.00	1.0e+00	SLC22A3
Pulse wave reflection index	1.99	1	0	0.0	0.00	1.0e+00	SLC22A3
Pulse rate	1.98	1	1	2.2	0.00	1.0e+00	FNDC4
High blood pressure (siblings)	1.94	2	0	0.0	0.00	1.0e+00	FNDC4 GIT1
Medication: Blood pressure	1.90	2	0	0.0	0.00	1.0e+00	GIT1 OPRL1
Crohns Disease (2017)	1.88	2	2	4.4	0.00	1.0e+00	FNDC4 NTN5
Hip circumference	1.87	7	3	6.7	-0.82	1.3e-02	ABCA1 FNDC4 HMGCR OPRL1 SLC22A3 TXNL4B VEGFB
Weight	1.84	5	3	6.7	-0.81	5.0e-02	FNDC4 HMGCR SLC22A3 SMARCA4 TXNL4B
Diabetes (father)	1.82	1	0	0.0	0.00	1.0e+00	FNDC4
Standing height	1.81	12	6	13.3	-0.71	3.3e-03	ABCG5 APOC2 CDKN2D FNDC4 GIT1 KANK2 NTN5 PIGV PSRC1 SLC22A3 SMARCA4 SPC24
Blood Eosinophil Count	1.78	12	6	13.3	-0.32	2.9e-01	ABO APOC2 CDKN2D DOCK7 LPL OPRL1 PAFAH1B2 PIGV RASA3 SMARCA4 TOMM40 ZNF259
Medication: Bendroflumethiazide	1.77	2	0	0.0	0.00	1.0e+00	NTN5 PIGV
Medication: Lisinopril	1.77	1	0	0.0	0.00	1.0e+00	RASA3
Diastolic blood pressure, automated reading	1.75	3	1	2.2	0.00	1.0e+00	ABO C19orf80 PIGV
Birth weight of first child	1.73	2	0	0.0	0.00	1.0e+00	OPRL1 SMARCA4
Type 2 Diabetes (T2D) (2012)	1.70	1	0	0.0	0.00	1.0e+00	VEGFB
Impedance of whole body	1.70	4	3	6.7	1.00	3.0e-03	ABO FNDC4 HMGCR OPRL1
Serious illness, injury or assault of a close relative in last 2 years	1.66	1	0	0.0	0.00	1.0e+00	NTN5
BMI	1.65	8	4	8.9	-0.22	6.0e-01	FNDC4 GIT1 HMGCR KANK2 LPL OPRL1 SLC22A3 TXNL4B
Height	1.62	16	11	24.4	-0.73	2.3e-04	ABCG5 ABO APOC2 C1orf89 CDKN2D FNDC4 GIT1 KANK2 LPL NTN5 PIGV PSRC1 SLC22A3 SMARCA4 SPC24 ZNF259
Blood Red Count	1.59	8	6	13.3	-0.18	6.7e-01	ABCG5 ABO FNDC4 GIT1 LPIN3 PVRL2 TXNL4B VEGFB
Arm fat mass (right)	1.59	6	1	2.2	-0.59	1.6e-01	ABO FNDC4 HMGCR PVRL2 SLC22A3 TXNL4B
Back pain experienced in last month	1.56	1	0	0.0	0.00	1.0e+00	APOB
Pulse wave Arterial Stiffness index	1.55	1	0	0.0	0.00	1.0e+00	VEGFB
High blood pressure (mother)	1.54	1	1	2.2	0.00	1.0e+00	PIGV
Arm fat mass (left)	1.54	6	1	2.2	-0.59	1.6e-01	ABO FNDC4 HMGCR PVRL2 SLC22A3 TXNL4B
Allergy	1.52	1	1	2.2	0.00	1.0e+00	ABO
Sitting height	1.51	9	2	4.4	-0.61	4.5e-02	ABCG5 FNDC4 KANK2 NTN5 PIGV SLC22A3 SMARCA4 SPC24 TXNL4B
Peak expiratory flow (PEF)	1.51	3	2	4.4	0.00	1.0e+00	ABO GIT1 NTN5
Rheumatoid Arthritis	1.50	2	0	0.0	0.00	1.0e+00	KANK2 OPRL1
Ovarian Cancer	1.49	1	0	0.0	0.00	1.0e+00	ABO
Leg fat mass (right)	1.49	6	1	2.2	-0.51	3.1e-01	FNDC4 GIT1 HMGCR PVRL2 SLC22A3 TXNL4B
Allergy or Eczema	1.48	4	1	2.2	0.99	1.1e-02	ABO APOC2 FNDC4 PVRL2
Mouth/teeth dental problems: Dentures	1.48	1	1	2.2	0.00	1.0e+00	NTN5
Body mass index (BMI)	1.47	5	1	2.2	-0.46	4.3e-01	FNDC4 GIT1 HMGCR PVRL2 TXNL4B
Forced expiratory volume in 1-second (FEV1), predicted	1.47	1	0	0.0	0.00	1.0e+00	SMARCA4
Arm fat percentage (right)	1.45	5	2	4.4	0.02	9.7e-01	ABO GIT1 HMGCR PVRL2 TXNL4B
Birth weight	1.45	1	0	0.0	0.00	1.0e+00	NTN5
Had menopause	1.44	1	0	0.0	0.00	1.0e+00	LPL
Leg fat mass (left)	1.44	4	1	2.2	-0.67	3.3e-01	FNDC4 HMGCR SLC22A3 TXNL4B
Had other major operations	1.42	1	0	0.0	0.00	1.0e+00	ABCG5
Pulse wave peak to peak time	1.41	1	0	0.0	0.00	1.0e+00	VEGFB
Arm fat percentage (left)	1.41	5	2	4.4	0.02	9.8e-01	ABO GIT1 HMGCR PVRL2 TXNL4B
Hand grip strength (right)	1.40	4	0	0.0	-0.60	4.0e-01	ABO FNDC4 PVRL2 SLC22A3
Whole body fat mass	1.40	4	2	4.4	-0.66	2.3e-01	HMGCR PVRL2 SLC22A3 TXNL4B
Myopia	1.40	1	0	0.0	0.00	1.0e+00	KANK2
Bipolar Disorder (2018)	1.39	1	0	0.0	0.00	1.0e+00	FNDC4
Impedance of leg (left)	1.38	5	2	4.4	0.76	1.4e-01	C1orf89 FNDC4 HMGCR LPL OPRL1
Pain experienced in last month	1.38	1	0	0.0	0.00	1.0e+00	OPRL1
Irritable Bowel Disease (IBD)	1.37	3	1	2.2	0.00	1.0e+00	FNDC4 NTN5 OPRL1
Seen doctor (GP) for nerves, anxiety, tension or depression	1.37	1	1	2.2	0.00	1.0e+00	LPIN3
Trunk fat mass	1.36	5	2	4.4	-0.52	2.9e-01	ABO HMGCR PVRL2 SLC22A3 TXNL4B
Relative age of first facial hair	1.34	1	1	2.2	0.00	1.0e+00	FNDC4
Hayfever, allergic rhinitis or eczema	1.34	2	0	0.0	0.00	1.0e+00	ABO PVRL2
Heel T-Score	1.33	6	3	6.7	-0.83	4.1e-02	ABO DOCK7 GIT1 HMGCR LPIN3 PSRC1
HbA1C	1.32	1	0	0.0	0.00	1.0e+00	VEGFB
Systolic blood pressure, automated reading	1.32	2	1	2.2	0.00	1.0e+00	OPRL1 PIGV
Impedance of leg (right)	1.31	4	2	4.4	0.98	2.4e-02	C1orf89 FNDC4 HMGCR OPRL1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.31	3	0	0.0	0.00	1.0e+00	ABO OPRL1 PVRL2
Crohns Disease (2012)	1.29	1	0	0.0	0.00	1.0e+00	FNDC4
Hypothyroidism (self reported)	1.27	2	0	0.0	0.00	1.0e+00	GIT1 NTN5
Mother's age at death	1.27	1	0	0.0	0.00	1.0e+00	ABO
Trunk fat percentage	1.26	5	2	4.4	-0.47	4.3e-01	ABO HMGCR PVRL2 SLC22A3 TXNL4B
Waist circumference	1.26	4	1	2.2	-0.66	3.4e-01	FNDC4 HMGCR PVRL2 TXNL4B
Leg fat percentage (right)	1.25	4	2	4.4	0.38	6.2e-01	GIT1 HMGCR KANK2 TXNL4B
Number of incorrect matches in round	1.24	2	0	0.0	0.00	1.0e+00	GIT1 NAT2
Body fat percentage	1.24	5	1	2.2	-0.05	9.4e-01	ABO GIT1 HMGCR PVRL2 TXNL4B
Number of operations (self-reported)	1.24	1	0	0.0	0.00	1.0e+00	ABCG5
Number of children fathered	1.23	1	0	0.0	0.00	1.0e+00	NTN5
Average weekly spirits intake	1.22	1	0	0.0	0.00	1.0e+00	NTN5
Asthma	1.21	1	0	0.0	0.00	1.0e+00	SMARCA4
Mouth/teeth dental problems	1.19	1	0	0.0	0.00	1.0e+00	NTN5
Forced vital capacity (FVC), Best measure	1.15	3	0	0.0	0.00	1.0e+00	GIT1 PVRL2 SMARCA4
Leg fat percentage (left)	1.15	3	1	2.2	0.00	1.0e+00	GIT1 HMGCR KANK2
Heel bone mineral density (BMD) T-score, automated (left)	1.13	2	0	0.0	0.00	1.0e+00	ABO GIT1
Heel bone mineral density (BMD) T-score, automated (right)	1.13	2	0	0.0	0.00	1.0e+00	ABO GIT1
Forced vital capacity (FVC)	1.12	3	1	2.2	0.00	1.0e+00	GIT1 PVRL2 SMARCA4
Alcohol usually taken with meals	1.10	1	0	0.0	0.00	1.0e+00	LPIN3
Forced expiratory volume in 1-second (FEV1), Best measure	1.08	3	0	0.0	-0.68	3.2e-01	ABO PVRL2 SMARCA4
Ulcerative Colitis (UC)	1.07	1	1	2.2	0.00	1.0e+00	OPRL1
Hand grip strength (left)	1.06	2	0	0.0	0.00	1.0e+00	ABO PVRL2
Asthma (self-reported)	1.06	1	0	0.0	0.00	1.0e+00	SMARCA4
Breast Cancer	1.05	1	0	0.0	0.00	1.0e+00	OPRL1
Intelligence (Savage-Jansen 2018)	1.04	2	0	0.0	0.00	1.0e+00	GIT1 TXNL4B
Forced expiratory volume in 1-second (FEV1)	1.04	4	0	0.0	-0.04	9.4e-01	ABO OPRL1 PVRL2 SMARCA4
Chronotype (morning person)	1.03	1	0	0.0	0.00	1.0e+00	NTN5
Age when periods started (menarche)	1.00	1	0	0.0	0.00	1.0e+00	NTN5
Lung FVC	0.98	4	1	2.2	-0.52	4.8e-01	ABO FNDC4 OPRL1 PVRL2
Schizophrenia vs Biploar Disorder	0.97	1	0	0.0	0.00	1.0e+00	FNDC4
Comparative body size at age 10	0.97	1	1	2.2	0.00	1.0e+00	NTN5
Hair/balding pattern: Pattern 4	0.89	1	0	0.0	0.00	1.0e+00	LPIN3
Qualifications: None of the above	0.88	1	0	0.0	0.00	1.0e+00	RASA3
Guilty feelings	0.84	1	0	0.0	0.00	1.0e+00	LPIN3
Hair/balding pattern: Pattern 3	0.80	1	0	0.0	0.00	1.0e+00	LPIN3
Tanning	0.25	1	1	2.2	0.00	1.0e+00	FNDC4
Hair Pigment	0.22	4	0	0.0	0.70	1.9e-01	FNDC4 OPRL1 PIGV SMARCA4

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Liver	2	0.279	1.8
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.362	1.8
GTEx	Brain Frontal Cortex BA9	1	0.108	1.6
GTEx	Prostate	0	0.000	1.6
GTEx	Skin Sun Exposed Lower leg	6	0.165	1.6
GTEx	Spleen	2	0.142	1.6
GTEx	Stomach	1	0.069	1.6
GTEx	Vagina	1	0.157	1.6
GTEx	Whole Blood	4	0.201	1.6
CommonMind	Brain Pre-frontal Cortex	9	0.167	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.194	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.195	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.314	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.6
GTEx	Adipose Subcutaneous	1	0.029	1.5
GTEx	Adipose Visceral Omentum	2	0.098	1.5
GTEx	Adrenal Gland	0	0.000	1.5
GTEx	Artery Aorta	3	0.101	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Artery Tibial	4	0.106	1.5
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.5
GTEx	Brain Cerebellum	1	0.050	1.5
GTEx	Brain Cortex	0	0.000	1.5
GTEx	Brain Hippocampus	0	0.000	1.5
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.5
GTEx	Breast Mammary Tissue	0	0.000	1.5
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.5
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.5
GTEx	Colon Transverse	0	0.000	1.5
GTEx	Esophagus Mucosa	6	0.181	1.5
GTEx	Esophagus Muscularis	5	0.155	1.5
GTEx	Heart Atrial Appendage	0	0.000	1.5
GTEx	Lung	0	0.000	1.5
GTEx	Muscle Skeletal	1	0.035	1.5
GTEx	Ovary	0	0.000	1.5
GTEx	Pituitary	0	0.000	1.5
GTEx	Skin Not Sun Exposed Suprapubic	3	0.122	1.5
GTEx	Small Intestine Terminal Ileum	0	0.000	1.5
GTEx	Thyroid	6	0.150	1.5
NTR	Blood	3	0.125	1.5
ROSMAP	Brain Pre-frontal Cortex	8	0.182	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	2	0.196	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.5
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	8	0.195	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	6	0.139	1.5
The Cancer Genome Atlas	Lung Adenocarcinoma	4	0.136	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	9	0.174	1.5
GTEx	Brain Hypothalamus	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
GTEx	Cells Transformed fibroblasts	6	0.143	1.4
GTEx	Colon Sigmoid	1	0.068	1.4
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Nerve Tibial	3	0.069	1.4
GTEx	Pancreas	1	0.061	1.4
GTEx	Testis	3	0.095	1.4
GTEx	Uterus	0	0.000	1.4
METSIM	Adipose	2	0.043	1.4
YFS	Blood	6	0.130	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	1	0.040	1.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.4
GTEx	Brain Caudate basal ganglia	1	0.109	1.3